We are excited to spotlight our collaboration with RevImmune, a clinical-stage biotech company advancing immunotherapies for infectious diseases, sepsis, and cancer. RevImmune's lead candidate, CYT107 — a glycosylated form of interleukin-7 (IL-7) — is currently in multiple Phase II trials and has been administered to over 500 patients, demonstrating a strong safety profile and promising results across various indications.

At INITS, we have been supporting RevImmune for several years across multiple facets of product development, including CMC, regulatory affairs, quality management, and IMP management. Our partnership is built on mutual trust and a shared commitment to advancing life-changing therapies.​

Here's what the RevImmune team had to say about our collaboration:​

"RevImmune has been working with INITS for several years on different aspects of product development (CMC/regulatory, Quality management, and IMP management). The team is very reactive and supportive. It's always a pleasure to interact with such a dynamic team."​

We are proud to contribute to RevImmune's mission and look forward to continuing our fruitful collaboration.​

Find all our testimonials on our website: https://inits.fr/​

#Partnership #Biotechnology #Immunotherapy #CMC #IMP #QualityAssurance #RegulatoryAffairs #Innovation #Biomanufacturing